3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Ovarian Neoplasms
15
Uterine Cervical Neoplasms
13
Fallopian Tube Neoplasms
4
Recurrence
3
Melanoma
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Carcinoma
2
Breast Neoplasms
2
Advanced Endometrial Cancer
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Endometrial Stromal
1
Platinum-resistant Recurrent Ovarian Cancer
1
Pelvic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
24
Nivolumab
15
Magnetic Resonance Spectroscopy
7
Ipilimumab
6
avelumab
5
atezolizumab
5
Specimen Handling
5
Docetaxel
4
lenvatinib
3
durvalumab
3
Paclitaxel
3
Cyclophosphamide
3
Carboplatin
3
fludarabine
2
cabozantinib
2
aldesleukin
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
FAPI-46
2
zanidatamab
1
veliparib
1
tislelizumab
1
spartalizumab
1
soluble LAG-3 protein, human
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
regorafenib
1
poly ICLC
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Injections
×
Gynecologic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled